ArticleAmerican journal of translational research2025
Reversal effect of sugammadex sodium on rocuronium-induced neuromuscular blockade in patients undergoing painless tracheoscopy.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the efficacy and safety of sugammadex sodium versus neostigmine for rocuronium-induced neuromuscular blockade during painless tracheoscopy.
methodsA retrospective analysis was conducted in 278 consecutive patients who underwent painless tracheoscopy under rocuronium anesthesia between January 2023 and May 2024. Patients received either sugammadex (n = 125) or neostigmine (n = 153) for muscle-relaxant reversal. Outcomes evaluated included train-of-four (TOF) recovery times (TOF ≥ 0.25, 0.75, 0.9), complete reversal rates, recovery metrics (eye-opening time, post-anesthesia care unit (PACU) stay) and complication rates. Correlations between baseline characteristics and TOF recovery times were also assessed.
resultsSugammadex significantly accelerated TOF recovery (all P < 0.001) and improved complete reversal rate (P = 0.013). Eye-opening and PACU times were reduced by 35.4% and 35.8%, respectively (both P < 0.001). The incidences of hypoxemia, bradycardia, and postoperative nausea and vomiting (PONV) were also decreased (all P < 0.05). Age, body mass index (BMI), and American Society of Anesthesiologists (ASA) class were positively correlated with TOF recovery time.
conclusionIn painless tracheoscopy, sugammadex sodium provides rapid and complete reversal of rocuronium, lowers postoperative complications, and improves perioperative efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.